MX2019013995A - Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. - Google Patents
Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.Info
- Publication number
- MX2019013995A MX2019013995A MX2019013995A MX2019013995A MX2019013995A MX 2019013995 A MX2019013995 A MX 2019013995A MX 2019013995 A MX2019013995 A MX 2019013995A MX 2019013995 A MX2019013995 A MX 2019013995A MX 2019013995 A MX2019013995 A MX 2019013995A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- associated antigen
- protein binding
- binding nkg2d
- nkg2d
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 abstract 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 abstract 2
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 1
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 1
- 102100032530 Glypican-3 Human genes 0.000 abstract 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 abstract 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 abstract 1
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 abstract 1
- 108030001694 Pappalysin-1 Proteins 0.000 abstract 1
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 abstract 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510169P | 2017-05-23 | 2017-05-23 | |
| US201762510168P | 2017-05-23 | 2017-05-23 | |
| US201762510167P | 2017-05-23 | 2017-05-23 | |
| US201762510137P | 2017-05-23 | 2017-05-23 | |
| US201762539425P | 2017-07-31 | 2017-07-31 | |
| PCT/US2018/034221 WO2018217945A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013995A true MX2019013995A (es) | 2020-07-29 |
Family
ID=64395873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013995A MX2019013995A (es) | 2017-05-23 | 2018-05-23 | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157226A1 (enExample) |
| EP (1) | EP3630181A4 (enExample) |
| JP (2) | JP2020522474A (enExample) |
| KR (1) | KR20200010429A (enExample) |
| CN (1) | CN111278460A (enExample) |
| AU (1) | AU2018273250A1 (enExample) |
| BR (1) | BR112019024620A2 (enExample) |
| CA (1) | CA3064567A1 (enExample) |
| IL (1) | IL270801A (enExample) |
| MX (1) | MX2019013995A (enExample) |
| WO (1) | WO2018217945A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12384851B2 (en) | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EP4137510A4 (en) * | 2020-04-16 | 2023-11-01 | YiChen Therapeutics Limited | PD-1 MUTANT POLYPEPTIDE AND PRODUCTION AND USE THEREOF |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| KR20240087855A (ko) * | 2021-09-29 | 2024-06-19 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 baff-r에 결합하는 단백질 |
| US20230203202A1 (en) * | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| MA71628A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Anticorps anti-gpnmb et leurs méthodes d'utilisation |
| TW202432584A (zh) | 2022-11-15 | 2024-08-16 | 美商嘉來克生命科學有限責任公司 | 抗papp-a抗體及其使用方法 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AR083705A1 (es) * | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| AU2012229048B2 (en) * | 2011-03-16 | 2016-01-21 | Amgen Inc | Fc variants |
| LT2900694T (lt) * | 2012-09-27 | 2018-11-12 | Merus N.V. | Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| EP3126384B1 (en) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| EP3152235B1 (en) * | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| CA2970986C (en) * | 2014-12-19 | 2021-10-26 | Biotecnol Limited | Fusion protein comprising three binding domains to 5t4 and cd3 |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| WO2016134371A2 (en) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| AU2016284866B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific antigen binding proteins |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048347A1 (en) * | 2016-09-01 | 2020-02-13 | Immunomab, Inc. | Bispecific antibodies |
| JP2020506971A (ja) * | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
-
2018
- 2018-05-23 EP EP18805878.8A patent/EP3630181A4/en not_active Withdrawn
- 2018-05-23 CN CN201880051761.6A patent/CN111278460A/zh active Pending
- 2018-05-23 US US16/615,231 patent/US20200157226A1/en not_active Abandoned
- 2018-05-23 MX MX2019013995A patent/MX2019013995A/es unknown
- 2018-05-23 BR BR112019024620-7A patent/BR112019024620A2/pt not_active Application Discontinuation
- 2018-05-23 AU AU2018273250A patent/AU2018273250A1/en not_active Abandoned
- 2018-05-23 WO PCT/US2018/034221 patent/WO2018217945A1/en not_active Ceased
- 2018-05-23 CA CA3064567A patent/CA3064567A1/en active Pending
- 2018-05-23 KR KR1020197037753A patent/KR20200010429A/ko not_active Ceased
- 2018-05-23 JP JP2019565011A patent/JP2020522474A/ja active Pending
-
2019
- 2019-11-20 IL IL270801A patent/IL270801A/en unknown
-
2022
- 2022-12-28 JP JP2022211728A patent/JP2023030174A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3064567A1 (en) | 2018-11-29 |
| RU2019142714A (ru) | 2021-06-23 |
| EP3630181A1 (en) | 2020-04-08 |
| KR20200010429A (ko) | 2020-01-30 |
| WO2018217945A1 (en) | 2018-11-29 |
| IL270801A (en) | 2020-01-30 |
| BR112019024620A2 (pt) | 2020-06-23 |
| JP2020522474A (ja) | 2020-07-30 |
| CN111278460A (zh) | 2020-06-12 |
| RU2019142714A3 (enExample) | 2021-10-22 |
| JP2023030174A (ja) | 2023-03-07 |
| US20200157226A1 (en) | 2020-05-21 |
| EP3630181A4 (en) | 2021-03-17 |
| AU2018273250A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013995A (es) | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. | |
| MX420258B (es) | Proteínas de unión a nkg2d, cd16 y nectina 4. | |
| MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
| ZA201905462B (en) | Proteins binding her2, nkg2d and cd16 | |
| MX2020002036A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. | |
| MX2019013998A (es) | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). | |
| MX2020001257A (es) | Proteinas que se unen a nkg2d, cd16 y flt3. | |
| MY205850A (en) | Proteins binding bcma, nkg2d and cd16 | |
| SA520420526B1 (ar) | Caix، بروتينات ربط متعددة النوعية تستهدف أوano1،أو ميسوثيلين، أوtrop2،أوcea، أو كلاودين-18.2 | |
| EP4491234A3 (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| MX2022004430A (es) | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). | |
| MX2020012905A (es) | Proteínas de unión multiespecíficas y mejoras con estas. | |
| MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
| MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
| MX2019014000A (es) | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. | |
| PL3802598T3 (pl) | Białka wiążące dll3/cd3 do leczenia nowotworów | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| MX2019009943A (es) | Proteínas que se unen a gd2, nkg2d y cd16. | |
| WO2019222449A8 (en) | Protein binding nkg2d, cd16 and a fibroblast activation protein | |
| GEP20227440B (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| IL290871A (en) | Pharmaceutical formulations and dosage regimens for multi-binding proteins that bind her2, nkg2d, and cd16 for cancer therapy | |
| PH12020550933A1 (en) | Antibodies binding ctla-4 and uses thereof | |
| PH12018500520A1 (en) | Cd3 binding polypeptides | |
| WO2018187356A3 (en) | Protein antigens and uses thereof |